Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Schrodinger Inc

Healthcare US SDGR

15.76USD
0.83(5.56%)

Last update at 2026-06-04T18:12:00Z

Day Range

14.8516.47
LowHigh

52 Week Range

20.7659.24
LowHigh

Fundamentals

  • Previous Close 14.93
  • Market Cap1606.94M
  • Volume1559407
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-209.15200M
  • Revenue TTM188.48M
  • Revenue Per Share TTM2.62
  • Gross Profit TTM 101.02M
  • Diluted EPS TTM-2.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -149.12600M -100.80800M -26.29200M -25.97200M -28.34800M
Minority interest 0.00300M -0.82600M -2.17400M 0.04M 0.04M
Net income -149.18900M -101.21900M -26.63700M -25.68100M -28.42500M
Selling general administrative 90.83M 64.01M 41.90M 27.04M 18.55M
Selling and marketing expenses 30.64M 22.15M 17.80M 21.36M 17.83M
Gross profit 101.02M 65.62M 63.47M 49.09M 42.94M
Reconciled depreciation 4.34M 2.85M 3.66M 3.64M 2.89M
Ebit -149.12300M -111.44300M -60.91600M -38.71500M -27.15700M
Ebitda -144.77900M -119.95500M -85.52100M -44.99700M -24.26300M
Depreciation and amortization 4.34M -8.51200M -24.60500M -6.28200M 2.89M
Non operating income net other - 10.63M 34.62M - -
Operating income -149.12300M -111.44300M -60.91600M -38.71500M -27.96900M
Other operating expenses 327.77M 249.37M 169.01M 124.26M 94.61M
Interest expense 0.00300M 22.82M 65.06M 23.77M 0.00000M
Tax provision 0.06M 0.41M 0.34M -0.29100M 0.08M
Interest income - 1.06M 2.25M 1.88M 0.43M
Net interest income - 1.06M 2.25M 1.88M 0.43M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.06M 0.41M 0.34M -0.29100M 0.08M
Total revenue 180.96M 137.93M 108.09M 85.54M 66.64M
Total operating expenses 247.84M 177.06M 124.39M 87.81M 70.91M
Cost of revenue 79.93M 72.31M 44.62M 36.45M 23.70M
Total other income expense net -0.00300M 10.63M 34.62M 12.74M -0.81200M
Discontinued operations - - - - -
Net income from continuing ops -149.18900M -101.21900M -26.63700M -25.68100M -28.42500M
Net income applicable to common shares -149.18600M -100.39300M -24.46300M -24.57100M -28.42500M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 802.96M 688.59M 756.49M 746.26M 155.27M
Intangible assets - 0.59M - - -
Earning assets - - - - -
Other current assets 9.93M 26.95M 16.84M 8.86M 6.97M
Total liab 254.40M 240.68M 199.40M 122.24M 248.59M
Total stockholder equity 548.56M 447.89M 557.07M 624.01M -93.36400M
Deferred long term liab - - 30.06M 41.16M -
Other current liab 43.76M 30.39M 25.72M 14.86M 10.86M
Common stock 0.72M 0.71M 0.71M 0.70M 0.06M
Capital stock 0.72M 0.71M 0.71M 0.70M 0.06M
Retained earnings -338.41800M -379.13800M -229.95200M -129.55900M -105.09600M
Other liab - 26.40M 30.36M 41.82M 3.10M
Good will 4.79M 4.79M - - -
Other assets - 3.31M 2.85M 2.35M 2.34M
Cash 161.07M 90.47M 120.27M 202.30M 25.99M
Cash and equivalents - - - - -
Total current liabilities 133.67M 108.80M 91.21M 73.20M 45.02M
Current deferred revenue 56.23M 57.93M 55.37M 45.40M 25.05M
Net debt -33.18400M 26.02M -40.39800M -190.53200M -11.51400M
Short term debt 16.87M 11.01M 2.04M 4.54M 5.58M
Short long term debt - - - - -
Short long term debt total 127.88M 116.49M 79.87M 11.76M 14.47M
Other stockholder equity 885.97M 828.70M 786.96M 6.29M -179.92500M
Property plant equipment - 120.23M 10.03M 5.14M 19.03M
Total current assets 567.80M 533.99M 625.06M 682.98M 118.54M
Long term investments 83.25M 25.68M 43.17M 45.66M 15.37M
Net tangible assets - 442.52M 557.07M 624.01M -93.36400M
Short term investments 307.69M 360.61M 456.21M 440.39M 59.84M
Net receivables 89.12M 69.09M 40.55M 35.38M 25.74M
Long term debt - - - - -
Inventory - -13.13700M -8.80700M -3.95500M -
Accounts payable 16.82M 9.47M 8.08M 8.40M 3.52M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - 0.01M 0.00400M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.28M -2.38200M -0.65100M 0.32M 0.02M
Additional paid in capital - - - - -
Common stock total equity - - 0.71M 0.70M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - - -229.95200M -129.55900M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 6.01M 3.31M 2.85M 2.35M 2.34M
Deferred long term asset charges - - - - -
Non current assets total 235.16M 154.60M 131.43M 63.28M 36.73M
Capital lease obligations 127.88M 116.49M 79.87M 11.76M 14.47M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 90.02M -9.64500M -379.18300M -53.85500M 11.19M
Change to liabilities -0.72400M 8.46M 68.34M 6.42M 8.41M
Total cashflows from investing activities 90.02M -16.81200M -381.72100M -53.85500M 11.19M
Net borrowings - - - - -
Total cash from financing activities 2.11M 7.95M 541.27M 28.68M 80.27M
Change to operating activities 7.30M 11.62M 3.87M 4.47M -3.85900M
Net income -149.18900M -101.21900M -26.63700M -25.68100M -28.42500M
Change in cash -27.55000M -79.52900M 176.31M -51.23000M 67.76M
Begin period cash flow 123.27M 202.80M 26.49M 77.72M 9.96M
End period cash flow 95.72M 123.27M 202.80M 26.49M 77.72M
Total cash from operating activities -119.68300M -70.66900M 16.76M -26.05900M -23.71100M
Issuance of capital stock 0.00000M 0.00000M 537.09M 30.44M 80.27M
Depreciation 4.34M 2.85M 3.66M 3.64M 2.89M
Other cashflows from investing activities - - - -52.01900M 16.45M
Dividends paid - - - - -
Change to inventory - 6.44M 7.34M 2.91M -3.85900M
Change to account receivables -23.69700M -0.32100M -12.74700M -5.03800M -4.27300M
Sale purchase of stock - 7.95M 215.67M 30.44M 80.27M
Other cashflows from financing activities 90.02M 7.95M 4.18M 28.14M 79.38M
Change to netincome 46.53M 28.41M 6.44M -9.42300M 1.53M
Capital expenditures 8.01M 7.17M 2.54M 1.84M 5.26M
Change receivables - -0.32100M -12.74700M - -
Cash flows other operating - -8.84300M -22.29700M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - -79.52900M 176.31M - -
Change in working capital -21.37500M 4.68M 59.18M 4.29M 0.28M
Stock based compensation 39.63M 26.49M 10.54M 2.19M 1.31M
Other non cash items 6.91M 0.81M 2.14M 1.05M -0.14900M
Free cash flow -127.69700M -77.83600M 14.22M -27.89500M -28.97000M

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SDGR
Schrodinger Inc		 0.83 5.56% 15.76 - - 8.83 3.49 7.28 -9.177
VEEV
Veeva Systems Inc Class A		 -0.03 0.02% 178.69 54.61 33.22 12.83 6.73 11.14 58.84
MTHRF
M3 Inc		 - -% 8.55 29.72 25.00 0.05 4.38 0.04 0.12
MTHRY
M3 Inc		 0.09 1.91% 4.80 31.84 26.25 0.05 4.60 0.04 0.12
BTSG
BrightSpring Health Services, Inc. Common Stock		 -3.425 5.63% 57.45 100.22 40.65 0.69 4.92 0.92 25.80

Reports Covered

Stock Research & News

View All

Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Schrodinger Inc

1540 Broadway, New York, NY, United States, 10036

Key Executives

Name Title Year Born
Dr. Ramy Farid Ph.D. CEO, Pres & Director 1964
Dr. Richard A. Friesner Ph.D. Co-Founder, Scientific Advisory Chairman and Director 1953
Mr. Kenneth Patrick Lorton Exec. VP & CTO 1984
Dr. Robert Lorne Abel Ph.D. Exec. VP, Chief Computational Scientist and Head of Modeling R&D 1982
Dr. Karen Akinsanya Ph.D. Pres of R&D Therapeutics 1968
Prof. William Goddard III Co-Founder & Scientific Advisor NA
Dr. Geoffrey Craig Porges MBBS Exec. VP & CFO NA
Mr. Shane Brauner Exec. VP & Chief Information Officer 1978
Ms. Jaren Irene Madden Sr. VP of Investor Relations & Corp. Communications NA
Ms. Yvonne Tran Esq. Exec. VP, Chief Legal Officer & Sec. 1971

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.